Promising combo tackles relapsed myeloma in early trial

NCT ID NCT01615029

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called daratumumab, given together with two standard treatments (lenalidomide and dexamethasone), in 45 people whose multiple myeloma had returned or stopped responding to prior therapy. The main goal was to check safety and see how many patients responded to the combination. The trial was completed and helped determine the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daratumumab (a targeted antibody) combined with lenalidomide and dexamethasone
What this could lead to: If successful, this combination could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to prior therapies.
What could go wrong: This is an early-phase trial with only 45 participants, so results may not apply to all patients. Side effects from the drug combination could be significant, and the treatment is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Study site

Boston, Massachusetts, United States
Study site

Copenhagen Ø, Denmark
Study site

Vejle, Denmark
Study site

Lille, France
Study site

Nantes, France
Study site

Vandœuvre-lès-Nancy, France
Study site

Utrecht, Netherlands
Study site

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.